China Mesalazine Market, by Route of Administration (Oral and Rectal), by Application (Ulcerative Colitis, Crohn's Disease, and Inflammatory Bowel Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022

Code : CMI5371

Pages :102

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

China Mesalazine Market - Driver

Increasing inorganic strategies, such as product launches by key market players, is expected to drive the growth of China mesalazine market. For instance, in July 2021, Tillotts Pharma AG, a pharmaceutical company, launched Asacol 800 mg tablets (mesalazine) as the first-line treatment for mild to moderate Ulcerative Colitis (UC) in China. It will strength mesalazine tablet formulation to the Chinese market to optimize the therapeutic options of patients living with ulcerative colitis in China.

China Mesalazine Market: Restraint

The availability of alternatives for mesalazine is expected to hamper the growth of China mesalazine market over the forecast period. Aminosalicylate (5-ASA) is considered the first line of treatment for ulcerative colitis. Moreover, other drug classes are indicated for the treatment of ulcerative colitis, inflammatory bowel disease, and Crohn’s disease. They are Corticosteroids, Immunomodulators, Targeted Synthetic Small Molecules (Immunosuppressants), and Biologic/Biosimilar Therapies (Monoclonal Antibodies). Furthermore, the introduction of biosimilars has revolutionized the control of Ulcerative Colitis (UC). It is a biological treatment for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. These medicines are less expensive than other drugs, making them more accessible to people in China.